Personalizing chemo: enzyme test may guide capecitabine dosing
NCT ID NCT04198727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if DPD levels can predict who benefits most from the drug, potentially leading to more personalized dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capecitabine
What this could lead to
If successful, this could help doctors tailor capecitabine doses based on a patient's DPD enzyme activity, improving treatment outcomes and reducing side effects.
What could go wrong
This is a mid-stage study with 155 participants, so results may not apply to all patients. The link between DPD activity and response is not yet proven, and the study is observational in nature.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Azuréen de Cancérologie
Mougins, 06250, France
-
Clinique Saint Jean
Cagnes-sur-Mer, 06800, France
-
Clinique St Georges
Nice, 06105, France
-
Hôpital Princesse Grâce
Monaco, 98000, Monaco